The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/t-cell lymphoma: A comparison with conventional staging methods

Journal of Nuclear Medicine

Volumn 54, Issue 7, 2013, Pages 1039-1044

  Moon, Seung Hwan ^a   Cho, Suk Kyong ^a   Kim, Won Seog ^a   Kim, Suk Jin ^a   Ahn, Yong Chan ^a   Choe, Yearn Seong ^a   Lee, Kyung Han ^a   Kim, Byung Tae ^a   Choi, Joon Young ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

18F FDG; PET CT; staging; nasal type NK T cell lymphoma

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR CLASSIFICATION; 18F-FDG; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; METHODOLOGY; MIDDLE AGED; NASAL-TYPE NK/T-CELL LYMPHOMA; NOSE TUMOR; PATHOLOGY; PET/CT; REPRODUCIBILITY; STAGING; T CELL LYMPHOMA;

18F-FDG; NASAL-TYPE NK/T-CELL LYMPHOMA; PET/CT; STAGING;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NOSE NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84879987757     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.113399     Document Type: Article

References (35)

1. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasaltype: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612-618.
2. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366-375.
3. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16:206-214.
4. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000;50:696-702.
5. Chen CY, Yao M, Tang JL, et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to Tcell lymphoma. Ann Oncol. 2004;15:1091-1096.
6. Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008;26:66-72.
7. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181-189.
8. Avilés A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol. 2000;22:215-220.
9. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594-5600.
10. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27:6027-6032.
11. Ahn HK, Suh C, Chuang SS, et al. Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol. 2012;23:2703-2707.
12. Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucosepositron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am. 2008;46:199-211.
13. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527-533.
14. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
15. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Positron emission tomography imaging for lymphoma. Curr Opin Oncol. 2005;17:441-445.
16. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685-1690.
17. Fujiwara H, Maeda Y, Nawa Y, et al. The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma. Eur J Haematol. 2011;87:123-129.
18. Wu HB, Wang QS, Wang MF, et al. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun. 2010;31:195-200.
19. Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma. 2008;8:94-99.
20. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83-87.
21. Carbone PP, Kaplan HS,MusshoffK, SmithersDW, TubianaM. Report of the CommitteeonHodgkin'sDiseaseStagingClassification. CancerRes.1971;31:1860-1861.
22. London K, Cross S, Onikul E, Dalla-Pozza L, Howman-Giles R. 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging. 2011;38:274-284.
23. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol. 2009;11:269-274.
24. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844-1854.
25. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006;24:146-150.
26. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J Clin Oncol. 2005;23:4577-4580.
27. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-578.
28. Nguyen XC, Lee WW, Amin AM, et al. Tumor burden assessed by the maximum standardized uptake value and greatest diameter on FDG-PET predicts prognosis in untreated diffuse large B-cell lymphoma. Nucl Med Mol Imaging. 2010;44:39-44.
29. Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2010;28:57-61.
30. Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010;35:571-575.
31. Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613-621.
32. Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49:1783-1789.
33. Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006;106:609-615.
34. Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166-174.
35. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46:958-963.